Arvinas Buy Rating Driven by Robust ARV-102 LRRK2 Degrader Data and Clear Neurodegeneration Development Path

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Arvinas Holding Company. The associated price target remains the same with $18.00.

Andrew Fein has given his Buy rating due to a combination of factors tied to the strength of Arvinas’s LRRK2 degrader program. He views the Phase 1 ARV-102 data in Parkinson’s patients as demonstrating robust, dose-related target knockdown in both blood and cerebrospinal fluid, coupled with a favorable safety and tolerability profile consistent with a well‑behaved clinical candidate.

Fein also believes the data provide a compelling proof‑of‑concept for the PROTAC approach in neurodegeneration, with protein elimination potentially offering advantages over traditional kinase inhibition. He sees a clear development path into progressive supranuclear palsy, including a planned Phase 1b in 2026 and possible registrational study soon after, and notes that upcoming competitor readouts could further validate the target and enhance ARV-102’s relative positioning, supporting a constructive outlook on Arvinas’s shares.

According to TipRanks, Fein is a 5-star analyst with an average return of 29.3% and a 56.39% success rate. Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, Vertex Pharmaceuticals, and Palvella Therapeutics.

In another report released today, Citi also assigned a Buy rating to the stock with a $21.00 price target.